[
    [
        {
            "time": "2020-Q1",
            "original_text": "药明康德2020一季度盈利同比下降21.59%至3.03亿元，盈利能力下降",
            "features": {
                "keywords": [
                    "药明康德",
                    "2020-Q1",
                    "盈利下降",
                    "净利润"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "药明康德2020一季度盈利同比下降21.59%至3.03亿元，盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-Q1",
            "original_text": "药明康德一季度营收增长15%，新增客户超过240家",
            "features": {
                "keywords": [
                    "药明康德",
                    "2020-Q1",
                    "营收增长",
                    "新增客户"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德一季度营收增长15%，新增客户超过240家",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-Q1",
            "original_text": "药明康德：一季度营收同比增长15.09%，各业务板块持续取得进展",
            "features": {
                "keywords": [
                    "药明康德",
                    "2020-Q1",
                    "营收增长",
                    "业务进展"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德：一季度营收同比增长15.09%，各业务板块持续取得进展",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-Q1",
            "original_text": "投资收益减少，药明康德2020年一季度净利同比下滑21.59%，盈利能力下降",
            "features": {
                "keywords": [
                    "药明康德",
                    "2020-Q1",
                    "投资收益减少",
                    "净利下滑"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "投资收益减少，药明康德2020年一季度净利同比下滑21.59%，盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-Q1",
            "original_text": "Q1营收同比增长15.1%，药明康德（02359）经调整净利润再次实现快速增长",
            "features": {
                "keywords": [
                    "药明康德",
                    "2020-Q1",
                    "营收增长",
                    "净利润增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Q1营收同比增长15.1%，药明康德（02359）经调整净利润再次实现快速增长",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-Q1",
            "original_text": "[国元医药]药明康德2020Q1点评：疫情影响较为有限，利润端受投资波动",
            "features": {
                "keywords": [
                    "药明康德",
                    "2020-Q1",
                    "疫情影响",
                    "利润波动"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "[国元医药]药明康德2020Q1点评：疫情影响较为有限，利润端受投资波动",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-Q1",
            "original_text": "[民生医药|点评]药明康德：新增客户和订单依然强劲，CDMO“漏斗效应”弹性大",
            "features": {
                "keywords": [
                    "药明康德",
                    "2020-Q1",
                    "新增客户",
                    "订单强劲",
                    "CDMO"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "[民生医药|点评]药明康德：新增客户和订单依然强劲，CDMO“漏斗效应”弹性大",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-Q1",
            "original_text": "[华西医药崔文亮团队]《药明康德点评报告：收入端略超市场预期，核心业务中国区实验室业务保持强劲增长》",
            "features": {
                "keywords": [
                    "药明康德",
                    "2020-Q1",
                    "收入增长",
                    "实验室业务"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "[华西医药崔文亮团队]《药明康德点评报告：收入端略超市场预期，核心业务中国区实验室业务保持强劲增长》",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]